...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Report Of Exempt Distribution.

"Resverlogix can fail without affecting Zenith"

man your just full of positives today lol

Have a great evening 

The saga continues 

GLTA 

Share
New Message
Please login to post a reply